Low Testosterone Lawsuits: The Gritty Details

October 01, 2015 – – Banville Law reports on specifics of allegations against low testosterone manufacturers. The lawsuit, which has been consolidated into multidistrict litigation, involves around 2,500 plaintiffs. These plaintiffs commonly allege that low t drugs have caused them serious health issues, including strokes, blood clots, and heart attacks. They also claim that marketing for the products is done in aggressive and misleading ways.

AbbVie is the first pharmaceutical manufacturing company to be addressed. Emerging details suggest that the suit alleges that AbbVie estimated an initial 1 million men are affected by hypogonadism, however, just after AndroGel became FDA approved, the company suddenly announced that its market encompassed at least 4 million men. The complaint continues, stating that just a few years later, that number turned into 20 million.

In the words of the complaint, “These numbers did not, and could not represent, the number of men with the conditions for which AndroGel is indicated, which are believed to be substantially smaller.”

The suit claims that pharmaceutical manufacturers of testosterone therapy treatments have knowingly chosen to market the products to more men than they should be, using advertising to aggressively target healthy men with normal symptoms of aging, rather than targeting only men with diagnosed hypogonadism, as the FDA approved.

Several aggressive marketing tactics are specifically cited by the suit, which are said to have been used across the board by all low t manufacturers. Allegations say that advertising indicated that men would look and feel younger, have their vitality back, and more. Plaintiffs also claim that manufacturers did not properly warn them about the potential health risks associated with the treatments.

After two studies seemed to link the drugs to blood clots and heart attacks, the FDA stepped up to make some changes. They required that all warning labels be properly revised to indicate the correct use of testosterone and the increased health risks it could cause.

The multidistrict litigation (MDL 2545) concerning these lawsuits will be presided over by Judge Matthew F. Kennelly in the United States District Court in the Northern District of Illinois. The next case management conference is currently scheduled for 3:30pm on October 15th, 2015. At this time, it is speculated that lawyers for the defendants and plaintiffs will review the status of their selection of cases for bellwether trials.

Those who would like more information on this topic, the upcoming trials, or have experienced serious side effects after using a low t drug, are encouraged contact Laurence Banville, Esq. of Banville Law. “You may be able to take legal action,” notes Banville. In addition to helping those interested in exploring their rights, Banville sponsors an online resource center dedicated to low testosterone information at LowTestosteroneCase.com. To speak with Laurence Banville, Esq. directly, call 917-809-6595.

###

Contact Banville Law:

Laurence Banville, Esq.
888-478-9711
info@banvillelaw.com
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60004507